MAPT and Alzheimer disease: The 18F-flortaucipir PET is not recommended to be clinically used to evaluate tauopathies other than AD (e.g., in other neurodegenerative tauopathies) [31], and the sensitivity of 18F-flortaucipir PET is limited in detecting early-stage tau pathology [32].